Editorial Team
... Read More
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Written By: Editorial Team | Published : December 27, 2012 5:42 PM IST
Drug firm Aurobindo Pharma Ltd today made an announcement that it has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Nafcillin injection, a drug used for treating bacterial infections.
Nafcillin for injection is a sterile semisynthetic penicillin (SSP) which is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have established susceptibility to the drug. It may be used prior to the availability of susceptibility test results to initiate therapy in suspected cases of resistant staphylococcal infections.
The company will manufacture and market Nafcillin for injection USP, packaged in 1g and 2g vials and Nafcillin for injection USP 10g/vial pharmacy bulk package in America. Statement released by the company said that the products were ready for launch.
